Compare CLIR & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLIR | CVM |
|---|---|---|
| Founded | 2008 | 1983 |
| Country | United States | United States |
| Employees | 15 | 44 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 28.1M |
| IPO Year | 2011 | 1996 |
| Metric | CLIR | CVM |
|---|---|---|
| Price | $3.87 | $1.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 7.3K | ★ 319.2K |
| Earning Date | 04-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $530,000.00 | $264,033.00 |
| Revenue This Year | $34.29 | N/A |
| Revenue Next Year | $67.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.39 | $0.89 |
| 52 Week High | $7.56 | $13.48 |
| Indicator | CLIR | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 68.91 |
| Support Level | $3.73 | $0.95 |
| Resistance Level | $4.27 | $1.86 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 58.12 | 98.04 |
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.